Recently approved NMDA blocker for the management of treatment resistant depression in adults is?
**Core Concept**
The question is testing the student's knowledge of a recently approved medication for treatment-resistant depression, specifically a NMDA receptor antagonist. NMDA receptors are a subtype of glutamate receptors involved in synaptic plasticity, learning, and memory.
**Why the Correct Answer is Right**
The correct answer is a NMDA receptor antagonist that has been approved for the treatment of treatment-resistant depression in adults. This medication works by blocking the action of glutamate at NMDA receptors, which may be involved in the pathophysiology of depression. The exact mechanism of action is not entirely understood, but it is thought to involve modulation of glutamatergic neurotransmission and subsequent changes in the activity of various neurotransmitter systems.
**Why Each Wrong Option is Incorrect**
* **Option A:** This is not a NMDA receptor antagonist, and it is not approved for the treatment of depression.
* **Option B:** This medication is actually a selective serotonin reuptake inhibitor (SSRI), which is a different class of antidepressants that work by increasing the levels of serotonin in the brain.
* **Option C:** This is a medication that is used to treat schizophrenia, not depression, and it works by blocking dopamine receptors, not NMDA receptors.
**Clinical Pearl / High-Yield Fact**
It's worth noting that the approval of new medications for treatment-resistant depression is often a significant development, as it provides new treatment options for patients who have not responded to other therapies. This can be a high-yield topic on exams, as it reflects the evolving landscape of psychiatric treatment.
**Correct Answer:** C. Esketamine